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INTRODUCTION 
Dapsone has been clinically used for the treatment 
of leprosy, Tuberculoid or Lepromatous Disease 
and malaria prophylaxis in some countries.  It is a 
potent anti-inflammatory and antiparasitic 
compound, and also finds application mainly in 
the treatment of bullous dermatoses and 
dermatitis herpetiformis.1 It is also being used for 
erythema elevatum diutinum, epidermolysis 
bullosa acquisita, linear IgA bullous dermatosis 
and cicatricial pemphigoid.2  The use of dapsone 
for Pneumocystis carinii pneumonia is still an off 
label use. While dapsone has demonstrated 
adequate safety and efficacy in these indications, 
there are few reports of patients in literature who 
have developed fatal or life-threatening drug 
related reactions.3 These ADRs with unknown 
mechanisms are hypersensitivity reactions to the 
drug and are a part of dapsone syndrome, also 
known as sulfone syndrome4, which is 
characterized by fever, lymphadenopathy, 
generalized rash and hepatic involvement as first 
described by Lowe and Smith.5 
 
CASE REPORT  
A 25 year male presented to the hospital with red 
erythematous maculopapular rash involving 
trunk, limbs and mucosal membrane for a few 
days and severe body pain for one week. 
Generalized lymphadenopathy and bilateral pedal 
edema were also evident. He had also mild 
hepatomegaly as per the USG of abdomen along 
with a history of fever with chills and cough with 
expectoration. The patient had been taking 
dapsone and rifampicin daily which had been 
prescribed by his family  physician for leprosy.  His  
 
chest X-ray was not significant for any finding. The 
blood picture was only remarkable for 
leukocytosis. His liver function tests showed 
elevation in transaminases (aspartate 
aminotransferase 190 U/L, alanine 
aminotransferase 219 U/L). The histopathological 
results revealed mononuclear inflammatory cell 
infiltration especially in perivascular region with 
few eosinophils, epidermis revealed mild 
spongiosis with parakeratotic stratum corneum. 
He was diagnosed as a case of DHS associated with 
respiratory tract infection. The patient was 
prescribed oral prednisolone for once daily use, 
tablet paracetamol 500 mg twice a day, 
ceftriaxone, tablet cetrizine, tramadol for pain, 
and white soft paraffin lotion for local application 
twice a day. He was also prescribed 
beclomethasone dipropionate ointment for local 
application on the erosions. The patient was 
advised to take tablet prednisolone for 10 days 
with subsequent tapering of the dose. On this 
treatment his clinical and hematological 
condition improved and child was discharged 
after a week of admission. After stopping the 
steroid, the patient developed another episode of 
dapsone syndrome following rebound effect. He 
was readmitted to the hospital after a month. The 
patient also developed steroid induced diabetes 
mellitus. He was prescribed injection insulin (4 U) 
thrice a day. Intravenous methylprednisolone was 
started to overcome the relapse of DHS. All the 
other medications in the previous regimen were 
restarted except prednisolone. The patient was 
followed up for 6 months and was in total clinical       
remission during the last visit.  
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The drug Dapsone is a component of the World Health Organization multidrug therapy being used against leprosy. Although it 
has shown a good efficacy during the years, a few subjects develop adverse drug reactions associated with dapsone .We report a 
case of a patient who was prescribed dapsone as part of multiple drug therapy for leprosy following which he developed Dapsone 
induced Hypersensitivity Syndrome (DHS). He was prescribed steroids with a tapering dose. His condition worsened after 
weaning of the oral steroids. He also developed steroid-induced diabetes which was stabilized using anti-diabetic drugs.  
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DISCUSSION  
With an increase in multidrug therapy for leprosy, 
there has been a rise in the incidence of DHS.6 
Dapsone hypersensitivity syndrome is neither 
dose dependent nor time dependent. Dapsone use 
can induce hemolytic anemia,3 renal injury,7 toxic 
effects on thyroid8. Patients experiencing DHS 
should discontinue the suspect drug immediately 
and should be managed with topical and systemic 
steroids, antibiotics, supportive care, nutritional 
support and fluid replacement.3 In the majority of 
the published literature, the patients' condition 
improved on permanent discontinuation of the 
drug and corrective treatment with steroids.8 In 
the present case the condition of the patient 
worsened as a relapse of DHS was encountered 
during weaning of the steroids. Moreover, the 
subject also developed steroid-induced diabetes. 
DHS has been reported in 0.5%–3.6% of patients 
taking dapsone and has a mortality rate of 9.9%.3 
In our case, dapsone was considered to be the 
probable cause of hypersensitivity due to the 
specific symptoms. Pharmacokinetic Interaction 
between Dapsone and Rifampicin has also been 
reported by Krishna DR et al who detailed that the 
dapsone level in blood, its half-life and AUC were 
significantly decreased with simultaneous 
increase in plasma clearance when it was 
administered concomitantly along with 
rifampicin.9 This kind of interaction could be a 
possible cause of adverse drug reaction in the 
present case. 
 
CONCLUSION 
Dapsone is being used widely for a number of 
diverse conditions across the globe. Healthcare 
professionals should be aware of this infrequent 
but potentially life-threatening severe form of 
adverse event that can prove to be fatal 
sometimes.    Dapsone     should     be     prescribed  
 
 
sensibly and judicious monitoring should be 
carried out throughout the course of treatment 
and the management with steroids should not be 
weaned abruptly. 
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